Share Name Share Symbol Market Type Share ISIN Share Description
Silence Ther. LSE:SLN London Ordinary Share GB00B9GTXM62 ORD 5P
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  +0.50p +0.42% 119.00p 118.00p 120.00p 120.00p 117.00p 120.00p 79,255 16:35:09
Industry Sector Turnover (m) Profit (m) EPS - Basic PE Ratio Market Cap (m)
Pharmaceuticals & Biotechnology 0.0 -3.8 -2.3 - 83.33

Silence Therapeutics PLC Notice of Results

24/08/2018 7:01am

UK Regulatory (RNS & others)

Silence Therapeutics (LSE:SLN)
Historical Stock Chart

2 Months : From Aug 2018 to Oct 2018

Click Here for more Silence Therapeutics Charts.


RNS Number : 7525Y

Silence Therapeutics PLC

24 August 2018

Silence Therapeutics Notice of Interim Results

24 AUGUST 2018

Silence Therapeutics plc, AIM:SLN ("Silence" or "the Company") a leader in the discovery, delivery, and development of novel RNA therapeutics for the treatment of serious diseases, will announce results for the six months ending 30 June 2018 on Tuesday 11 September 2018.

Dr. David Horn Solomon, Chief Executive Officer and David Ellam, Chief Financial Officer, will host a live conference call for analysts at 12.00pm BST on the day of the results.


 Silence Therapeutics plc                           Tel: +44 (0) 20 3457 
  Dr. David Horn Solomon, Chief Executive Officer                   6900 
  Dr. Andy Richards CBE, Interim Chair 
  David Ellam, Chief Financial Officer 
 Peel Hunt LLP (Nominated Adviser and Broker)       Tel: +44 (0) 20 7418 
  James Steel/ Oliver Jackson                                       8900 
 European IR                                        Tel: +44 (0) 20 3709 
  Consilium Strategic Communications                                5700 
  Mary-Jane Elliott, Angela Gray 
 US IR                                                 Tel: +1 (212) 213 
  Burns McClellan                                                   0006 
  Lisa Burns, John Grimaldi, Jill Steier 

Notes to Editors

About Silence Therapeutics plc

Silence Therapeutics is developing a new generation of medicines by harnessing the body's natural mechanism of RNA interference, or RNAi, within its cells. Our proprietary technology can selectively inhibit any gene in the genome, specifically silencing the production of disease-causing proteins. Using our enabling delivery systems, we have achieved an additional level of specificity by delivering our therapeutic RNA molecules exclusively to target cells. Silence's proprietary RNA chemistries and delivery systems are designed to improve the stability of our molecules and enhance effective delivery to target cells, providing a powerful modular technology well suited to tackle life-threatening diseases. For more information, please visit:

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact or visit



(END) Dow Jones Newswires

August 24, 2018 02:01 ET (06:01 GMT)

1 Year Silence Therapeutics Chart

1 Year Silence Therapeutics Chart

1 Month Silence Therapeutics Chart

1 Month Silence Therapeutics Chart
Your Recent History
Gulf Keyst..
FTSE 100
UK Sterlin..
Stocks you've viewed will appear in this box, letting you easily return to quotes you've seen previously.

Register now to create your own custom streaming stock watchlist.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P:43 V:gb D:20181016 20:56:11